telithromycin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Respiratory Tract Infections

Conditions

Respiratory Tract Infections

Trial Timeline

Feb 1, 2005 → Dec 1, 2005

NCT ID

NCT00261105

About telithromycin

telithromycin is a approved stage product being developed by Sanofi for Respiratory Tract Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00261105. Target conditions include Respiratory Tract Infections.

What happened to similar drugs?

4 of 20 similar drugs in Respiratory Tract Infections were approved

Approved (4) Terminated (1) Active (15)

🔄mRNA-1345ModernaPhase 3

✅Zopapogene imadenovec (Zopa)PrecigenApproved

✅YMC026 + PlaceboYuhanApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00288223	Approved	Terminated	Jan 1, 2006	Jan 1, 2007	Bronchitis, Chronic
NCT00261105	Approved	Completed	Feb 1, 2005	Dec 1, 2005	Respiratory Tract Infections
NCT00174694	Approved	Completed	Nov 1, 2004	—	Sinusitis
NCT00546676	Approved	Completed	May 1, 2004	Dec 1, 2004	Community Acquired Pneumonia (CAP)
NCT00132938	Approved	Completed	Jan 1, 2004	May 1, 2006	Chronic Bronchitis
NCT00538018	Approved	Completed	Jan 1, 2003	Jun 1, 2004	Pneumonia
NCT00273520	Phase 3	Completed	Jan 1, 2003	May 1, 2004	Asthma
NCT00537563	Phase 3	Completed	Dec 1, 2002	Sep 1, 2003	Maxillary Sinusitis
NCT00538148	Approved	Completed	Nov 1, 2002	Sep 1, 2004	Bronchitis, Chronic

Competing Products

20 competing products in Respiratory Tract Infections

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 1	0
mRNA-1345	Moderna	Phase 2	0
mRNA-1345	Moderna	Phase 2	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Preclinical	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 1	0
Zopapogene imadenovec (Zopa)	Precigen	Approved	44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	30
agenT-797	MiNK Therapeutics	Phase 1	19
YMC026 + Placebo	Yuhan	Approved	43
VN-0200 + Placebo	Daiichi Sankyo	Phase 1	29
VN-0200	Daiichi Sankyo	Phase 2	35
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	32
S-337395 + Placebo	Shionogi	Phase 2	42
Sivelestat	Eli Lilly	Phase 1/2	32